HIV

Top news of the week from Specialty Pharmacy Times.

With this approval, patients who have never been treated have the option of a 2-drug regimen in a single tablet, as opposed to the standard-of-care 3-drug regimen for HIV.

With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.

For the study, the researchers assessed whether a slow-release, long-acting, implantable naltrexone could improve outcomes for patients with HIV and opioid addiction.

An implantable form of naltrexone was more effective in improving HIV outcomes in patients compared with oral naltrexone.

HIV infection is associated with higher rates of hepatitis C replication.

The IAVI WOO1 study is one of the first clinical trials of a native-like Env trimer and the first time that this particular trimer is being evaluated in humans

The goals are to assess the candidate’s safety and to determine if the vaccination induces the human immune system to produce proteins called neutralizing antibodies.

An updated transmission model indicates that most new HIV infections occur due to a lack of diagnosis and treatment.

Study finds patients with negative beliefs about medications may be more likely to experience adverse effects when taking antiretroviral therapy.

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

A recently presented study indicates that while overall HIV mortality is declining, the rate of opioid overdose deaths in HIV patients is increasing.

Data compiled from a recent study show that this therapy was highly effective in preventing SHIV infection in a macaque model mimicking vaginal transmission of the virus.

Top news of the day from across the health care industry.

If approved, rilpivirine plus cabotegravir would be the first monthly dosing option for adult patients with HIV.

Recently approved by the US Food and Drug Administration (FDA), the Biktarvyregimen is indicated for the treatment of adults with HIV-1 who have no history of antiretroviral therapy.

An individual treated for HIV is believed to be in long-term remission, according to experts in the United Kingdom. 'The London Patient’ is only the second documented case of sustained remission for HIV infection.

Top news of the day from across the health care landscape.

Many women are unaware of HIV pre-exposure prophylaxis (PrEP) but show a keen interest in spreading the word once they learn about the option, according a recent study in the journal Contraception.

According to the CDC, major interventions are in need among at-risk populations in order to reach a goal of 90% decrease of HIV infections in 10 years.

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk.

Prevalence of cognitive impairment has increased among the HIV population while services for diagnosing and treating afflicted individuals remains scarce.

It is critical that they understand how to select and use these products to obtain accurate results.

In a new study, a team of investigators looked at data from a clinical trial testing 3 different ART regimens in order to determine the factors that can lead to enlarging waistlines in patients with HIV.

African Americans are disproportionately affected by HIV infection in the United States.